News Article | December 20, 2016
Part 1 of Series: Routes to Address the Real Challenges in Serialisation TORONTO, ON--(Marketwired - December 20, 2016) - During this webinar, Christian Groß, Manager of Packaging Technology and Project Manager of Serialisation at Aesica Pharmaceuticals will discuss the industry's preparedness for serialisation legislation and Aesica's serialisation solution, from concept to delivery. The live event takes place on Tuesday, January 17, 2016 at 11am EST (4pm GMT). Counterfeit drugs account for approximately $75 billion in global annual losses. To address this, anti-counterfeiting measures, such as serialisation, are making packaging as important as the drug it is tasked with protecting. Serialisation is a means to track and trace products, and legislation is already enforced in countries like Brazil, South Korea and China. It is due to come into effect in the US in 2017 and in all European countries by Feb 2019 for all prescription drugs. Serialisation systems must be configurable to meet the needs of the country in which the end product is to be distributed. In order for contract manufacturers, like Aesica, to be able to continue to serve their pharmaceutical customers, they must implement a serialisation capability that is able to deliver the required complexity and flexibly. By attending this session, viewers will: To learn more about this event visit: Pharmaceutical Serialisation - The Challenges We, As a CDMO, Are Facing Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com
Lee D.S.,University of Nottingham |
Amara Z.,University of Nottingham |
Poliakoff M.,University of Nottingham |
Harman T.,Aesica Pharmaceuticals |
And 5 more authors.
Organic Process Research and Development | Year: 2015
Methods for the batch scale up of DABAL-Me3 promoted direct ester to amide synthesis have been demonstrated at 10-100 g scales using a tert-amide model compound. Procedures for 20 g scale couplings in standard laboratory glassware and up to 0.1 kg in industry-standard jacketed glass reactors in near quantitative yields are given. A derivative of the anticancer agent Imatinib (Gleevec) has been synthesized on a 26 g scale (98% yield, >98% purity) establishing DABAL-Me3 as a potential alternative for the synthesis of amides in API scale preparations. Continuous flow methodology provides a method for larger scales (productivities of >50 g h-1). In addition, nitriles were coupled to primary amines and hydrazines with DABAL-Me3, resulting in the clean formation of free amidines (16 examples) and amidrazones. © 2015 American Chemical Society.
Dubois N.,University of Nottingham |
Glynn D.,University of Nottingham |
McInally T.,University of Nottingham |
Rhodes B.,Aesica Pharmaceuticals |
And 3 more authors.
Tetrahedron | Year: 2013
The range and utility of DABAL-Me3 couplings of methyl esters and free carboxylic acids with primary and secondary amines under a variety of conditions (reflux, sealed tube, microwave) has been compared for a significant range of coupling partners of relevance to the preparation of amides of interest in pharmaceutical chemistry. Commercial microwave reactors promote the fastest couplings and allow the use of significantly sterically hindered amines (primary and secondary) and carboxylic acids derivatives. The influence of microwave energy on the reaction system was shown to be typically related to thermal effects (over-pressuring and superheating). © 2013 Elsevier Ltd. All rights reserved.
Gautier F.-M.,University of Sheffield |
Jones S.,University of Sheffield |
Li X.,University of Sheffield |
Martin S.J.,Aesica Pharmaceuticals
Organic and Biomolecular Chemistry | Year: 2011
A highly active organocatalyst has been shown to affect the asymmetric reductive amination of ketones producing both aromatic and aliphatic amines. At 1 mol% catalyst loading, a series of structurally diverse chiral amines were quickly and economically prepared with good enantioselectivity and generally useful yield. The efficient synthesis of the calcimimetic (+)-NPS R-568 (67%, 89% ee) demonstrated the synthetic applicability of this methodology. © 2011 The Royal Society of Chemistry.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 141.03K | Year: 2014
A consortium comprising of Aesica Pharmaceuticals, Biocatalysts Ltd, CatScI Ltd and Charnwood Technical Consulting has been established as part of the Sustainable High-Value Chemical Manufacture through Industrial Biotechnology (IB) 2 competition from the TSB. The key goal of the project is to identify novel IB routes to an active pharmaceutical ingredient (API) that is currently manufactured through traditional chemical manufacturing techniques. The new technology has the potential to significantly reduce manufacturing costs whilst concomitantly allowing an increased output of the API with less manufacturing equipment. Additionally, this will have the added benefits of generating a more sustainable process as it will be more energy efficient and less reliant on hydrocarbon based technologies. A successful project will allow the consortium to compete with manufacture in low-cost economies and help ensure that production of this critical API continues in the United Kingdom.
Aesica Pharmaceuticals | Date: 2013-09-20
There is described (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid, or a salt or ester thereof, having substantially limited amounts of specific impurities associated with the synthesis and purification of the (S)-(+)-2-(2-fluoro-4-biphenylyl) propionic acid.
Aesica Pharmaceuticals | Date: 2012-02-21
Pharmaceutical preparations for the treatment of inflammation, arthritis, dementia, cancer, pain or mood disorders, such as, anxiety, depression and dysthymia.